1. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. Issue 1 (December 2016) Authors: Schouten, Philip; Dackus, Gwen; Marchetti, Serena; van Tinteren, Harm; Sonke, Gabe; Schellens, Jan; Linn, Sabine Journal: Trials Issue: Volume 17:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗